In vitro hemolysis: guidance for the pharmaceutical scientist.

Pharmaceutical excipients are commonly incorporated into parenteral formulations to increase solubility and stability of active pharmaceutical ingredients. The biocompatibility of these excipients is an important consideration during formulation development. Despite the importance of hemolytic potential of parenteral formulations, there is considerable contradictory information in the literature related to the hemolytic potential of various excipients. The hemolytic potential of various formulation vehicles in dog, rabbit, and human blood by means of an in vitro hemolysis assay is compared. The selected formulation vehicles are found in currently marketed drug products. The guidance presented here considers formulations with a hemolysis value of <10% to be nonhemolytic while values > 25% to be at risk for hemolysis.

[1]  Samuel H. Yalkowsky,et al.  Lysis of human red blood cells 2: effect of contact time on cosolvent induced hemolysis , 1997 .

[2]  S Sweetana,et al.  Solubility principles and practices for parenteral drug dosage form development. , 1996, PDA journal of pharmaceutical science and technology.

[3]  S Nema,et al.  Excipients and their use in injectable products. , 1997, PDA journal of pharmaceutical science and technology.

[4]  K W Reed,et al.  Lysis of human red blood cells in the presence of various cosolvents. , 1985, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.

[5]  F L Fort,et al.  Hemolysis study of aqueous polyethylene glycol 400, propylene glycol and ethanol combinations in vivo and in vitro. , 1984, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.

[6]  J. Adams,et al.  Isotonic solutions. II. The permeability of red corpuscles to various substances , 1944 .

[7]  S. Yalkowsky,et al.  Lysis of human red blood cells. 4. Comparison of in vitro and in vivo hemolysis data. , 1997, Journal of pharmaceutical sciences.

[8]  R. Strickley.  Parenteral formulations of small molecules therapeutics marketed in the United States (1999)--Part I. , 1999, PDA journal of pharmaceutical science and technology.